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Intraoperative detection of somatostatin-receptor-positive neuroendocrine
tumours using indium-111-labelled DTPA-D-Phel-octreotide
B W ingberg', E Forssell-Aronsson2, L-E Tisell', 0 Nilsson3, M Fjalling4 and H Ahlman'
Departments ofSurgery', Radiation Physics2, Pathology3 and Division ofNuclear Medicine4, Sahlgrenska Hospital, Gothenburg,
Sweden.
Summary After injection of "'In-labelled DTPA-D-Phel-octreotide, intraoperative tumour localisation was
performed using a scintillation detector in 23 patients with neuroendocrine tumours. Count rates from suspect
tumour lesions and adjacent normal tissue were expressed as a ratio before (Rin situ) and after (Rex vi,,) excision.
"'In activity concentration ratios of tumour tissue to blood (T/B) were determined in a gamma counter. In
patients with midgut carcinoids, (all scintigraphy positive), false Rm, situ recordings were found in 4/29
macroscopically identified tumours. T/B ratios were all high (27-650). In patients with medullary thyroid
carcinomas (eight out of ten scintigraphy positive), misleading Rin situ results were found in 4/37
macroscopically identified tumours. T/B ratios were lower (3-39) than those seen in midgut carcinoids.
Two out of four patients with endocrine pancreatic tumours had positive scintigraphy, reliable intraoperative
measurements and very high T/B ratios (910-1500). One patient with a gastric carcinoid had correct
measurements in situ and ex vivo with high T/B ratios (71-210). In situ measurements added little information
to preoperative scintigraphy and surgical findings using the present detection system. Rex vivo measurements
were more reliable. The very high T/B ratios seen in midgut carcinoids and some endocrine pancreatic tumours
would be favourable for future radiation therapy via somatostatin receptors.
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In autoradiographic studies and studies of tumour cell
membranes, somatostatin receptors have been demonstrated
on several kinds of neuroendocrine tumours (Reubi et al.,
1987, 1990). Five different somatostatin receptor subtypes
have been identified so far and their sequences have been
determined in man and in the rat. They all belong to the
superfamily of receptors with seven transmembrane domains
coupled to G-proteins. The widely used somatostatin
analogue octreotide binds to the type 2 receptor with high
affinity, but also to a lesser degree to the type 3 and 5
receptors (Bruns et al., 1994). By using radiolabelled
octreotide ("'In-labelled DTPA-D-Phe'-octreotide or 1231_
labelled Tyr3-octreotide) a sensitive scintigraphic technique
for localisation of somatostatin receptor-positive tumours has
been developed (Bakker et al., 1991; Lamberts et al., 1990).
The high sensitivity and specificity of the scintigraphic
method in midgut carcinoid tumours (Ahlman et al., 1994)
form the basis of the present study. We have evaluated the
use of a handheld scintillation detector for intraoperative
localisation of somatostatin receptor-positive tumours in
addition to preoperative scintigraphy. The intraoperative
measurements in situ and after excision (ex vivo) were
compared with determinations of "'In activity-concentration
ratios in tissue and blood as well as histopathological
findings. Three groups of patients with neuroendocrine
tumours were studied: midgut carcinoids (MCs); medullary
thyroid carcinomas (MTCs); and a mixed group, including
endocrine pancreatic tumours (EPTs), a gastric carcinoid
tumour and a neuroendocrine carcinoma.
Material and methods
Protocol
Tumour localisation was assessed in 23 patients by
scintigraphy and intraoperative scintillation detection after
i.v. injection of "'In-labelled DTPA-D-Phe'-octreotide.
Scintigraphy was performed before surgery and 1-2 days
after surgery without repeated injection of the radiopharma-
ceutical. As the optimal interval between injection and
surgery has not yet been established, five different time
intervals (24, 48, 72, 120 and 168 h) were used.
Patient material
Seven patients had MCs with lymph node and hepatic
metastases and elevated 5-HIAA levels (1206 + 452 pmol
24 h-i; ref. <50). Three of these patients (nos. 1, 2 and 6)
had previously undergone intestinal resection and clearance
of regional lymph node metastases. The other four patients
underwent primary surgery for metastatic disease.
Ten patients had residual MTCs after previous total
thyroidectomy and regional lymph node clearance (Table I).
They had been subjected to 1-4 neck dissections owing to
recurrent tumour. They all had elevated calcitonin levels at
pentagastrin provocation tests showing residual disease.
Another group comprised six patients with various
neuroendocrine tumours (Table I). Three of them underwent
primary surgery; patients no. 19 and 21 with EPTs without
metastatic spread [sporadic insulinoma and glucagonoma as
part of a multiple endocrine neoplasia (MEN I) syndrome],
and patient no. 18 with a metastatic gastric carcinoid. Two
patients with MEN I syndromes (patients no. 20 and 22) had
surgical exploration performed owing to the clinical suspicion
of recurrent pancreatic tumours. Another patient was
operated owing to metastatic neuroendocrine carcinoma of
the uterine cervix (patient no. 23).
Scintigraphy
Each patient received 10-20 Mg of "'.In-labelled DTPA-D-
Phe'-octreotide by i.v. injection 24-168 h before surgery. The
administered "'In activity was 140-300 MBq (> 98% of the
activity was peptide bound). No side-effects were observed.
Imaging was done 24 h after injection of the radiopharma-
ceutical. A gamma camera (General Electric 400 AC/T,
London, UK), equipped with a medium energy parallel-hole
collimator connected to a GE STARCAM computer system,
was used. Data acquisition was performed in a dual window
setting of 173 and 247 keV and evaluated on a GE STAR
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3000 system. Static anterior and posterior images from the
base of the skull to the pelvis were taken in all patients. The
static images were acquired in a 128 x 128 matrix for 10 min,
or until 500 000 counts were collected.
Single photon emission computerised tomography
(SPECT) was performed in a 128 x 128 matrix, using a 360°
rotation in 64 steps with 30 s per step. Prefiltration was
performed using a Hanning filter with a cut-off frequency of
0.7 cm-' and transaxial slices were reconstructed with a ramp
filter.
Scintillation detector and intraoperative measurements
The scintillation detector system (TecProbe 2000, Stratec
Elektronik, Birkenfeld, Germany) was equipped with a
handheld 17 x 2 cm silver-anodised aluminium tube, contain-
ing a caesium iodide crystal collimated with a lead shield
(aperture diameter 8 mm over a length of 10 mm). The probe
was connected to a portable ratemeter. The energy window
was 140-200 keV. A sterile dressing was drawn over the
probe, which was held close to the tissue examined.
With the scintillation detector the mean count rates in situ
over the suspect tumour lesion and the adjacent normal tissue
were recorded. The ratio, Rin si,u, between the two measure-
ments was calculated. Three to five recordings were
performed with the detector held perpendicular to each
tissue. Each recording lasted 3-10 s. To avoid contribution
from "'In activity from tissues with high activity concentra-
tion, e.g. liver, spleen, and kidneys, the probe was directed
away from these tissues, but extra shielding was not used
mainly owing to restricted anatomical space. The count rates
of excised tumour and normal tissue were also measured ex
vivo and the ratio Rex vivo, was calculated. All neck
explorations were performed by one surgeon and all
abdominal explorations by another surgeon in order to
minimise interindividual variability. Both surgeons were
experienced endocrine surgeons working with minimal
traumatic technique in all surgical fields.
Measurements of tissue samples
Before histopathological examination the surgical specimens
together with blood samples drawn during surgery were
weighed and the "'In activity concentration was measured in
a calibrated gamma counter equipped with a sodium iodide
well crystal (diameter 7.6 cm, length 7.6 cm, Harshaw, De
Meern, Holland). The hole in the crystal had a diameter of
3 cm and a depth of 6 cm. A single-channel pulse-height
analyser (Elscint, Haifa, Israel) was used. Corrections were
made for background activity and radioactive decay. Tissue
(Ti) to blood (B) "'In activity concentrations ratios, Ti/B
were calculated. Tumour (T) to blood (B) "'In activity
concentrations ratios (T/B) were calculated for histology-
proven tumour lesions.
Statistical analyses of intraoperative measurements
The standard deviation of the difference between the mean
number of counts from suspect tumour tissue (Ti) and
normal tissue (N) was estimated:
VT= Ti+N = /Ti'tTinTi + N tNnN
where Ti' and N' are mean count rates from suspect tumour
tissue and normal tissue, tTi and tN are integration times and
nTl and nN number of measurements for suspect tumour
tissue and normal tissue respectively. If the difference
between the mean numbers of counts from suspect tumour
tissue and normal tissue exceeded two standard deviations,
the difference was regarded as statistically significant (P <
0.05).
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Results
Midgut carcinoid tumours
Preoperative scintigraphy was positive for lymph node and
hepatic metastases in all MC patients (Table I). The primary
tumour was visualised in three of four patients studied. With
intraoperative use of the scintillation detector Rimsitu and Rex
vivo measurements were performed. In situ measurements of
macroscopically identified tumours gave erroneous results in
4/29 lesions (three false negative and one false positive); ex
vivo in 2/24 lesions (one false negative and one false positive).
One lymph node with microscopic tumour growth could not
be verified by probe measurements either in vivo or ex vivo.
The T/B ratios for MC tumours varied between 27 and
650 and were only a little influenced by time; even 7 days
after injection of the radiopharmaceutical the T/B ratios
remained very high in this tumour type (Table I).
The results of probe measurements and Ti/B calculations
in an MC patient (no. 3) undergoing primary surgery 48 h
after injection are shown in Figure 1. In situ the scintillation
detector correctly indicated tumour in regional lymph nodes
and hepatic lesions, but gave a false-positive result of a
parametrial cyst. The primary tumour gave a false-negative
reading despite a positive scintigraphic finding. The
discrimination was improved by using the scintillation
detector ex vivo (Figure 1). The best discrimination was,
however, obtained from Ti/B ratios. In this patient, normal
tissues had ratios varying between 5 and 11 and tumour
tissues had ratios between 51 and 220.
a
Medullary thyroid carcinomas
Eight out of ten patients had positive findings at
scintigraphy. At surgery, in situ measurements of macro-
scopically identified tumours gave misleading results in 4/37
lesions (all false negative); ex vivo in 1 out of 13 lesions
(false negative). One lymph node with microscopic tumour
growth could not be verified by the scintillation detector
either in situ or ex vivo. In three patients no tumour was
found at neck re-exploration and intraoperative measure-
ments were accordingly negative. One of these patients had
a positive scintigraphy finding owing to a skeletal metastasis
(patient no. 17).
The T/B ratios for MTC tumours seemed to be little
influenced by time, but they were considerably lower (3-39)
than those seen in MC tumours (Table I).
The results of probe measurements and Ti/B calculations
in an MTC patient (no. 11) undergoing repeat neck
exploration 48 h after injection is shown in Figure 2. In situ
the probe correctly discriminated between tumour in lymph
nodes vs normal lymph nodes and fat tissue. The ex vivo
ratios were increased in comparison with in situ ratios. The
Ti/B ratios for normal tissues varied between 3.8 and 5.7 in
comparison with 31 and 32 for tumour tissue.
Other neuroendocrine tumours
In situ measurements of a macroscopically identified EPT
patient (no. 21) with positive scintigraphy (glucagonoma)
b
Localisation Type of Histopathological Rinsitu Rexvivo Ti/B
of tissue tissue tumour finding
Abdomen Primary tumour positive 1.0 - 51
Lymph node positive 1.4 4.3* 56
Hepatic metastasis positive 1.8* - 220
Pelvis Uterine myoma negative 1.1 1.5 11
Parametrial cyst negative 1.4* 1.5 5
Figure 1 Intraoperative findings with scintillation detection and tissue to blood (Ti/B) ratios of "'In activity in a patient with
disseminated midgut carcinoid tumour. In the preoperative (a) scintigram the primary tumour (arrow) and bilobar liver metastases
are seen together with background activity in kidneys (K), liver and spleen. At surgery, the primary tumour, regional lymph nodes,
a liver metastasis and benign pelvic lesions were excised. Postoperative (b) scintigraphy shows remaining liver metastases and
background activity. *Significantly higher count rates from tumour than from adjacent normal tissue (P<0.05). R, right, L, left.["'In] DTPA-D-Phel-octreotide in tumour detection
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gave correct information (Figure 3). With ex vivo measure-
ments correct information was obtained in tumours both
from patients no. 20 and 21 (MEN I proinsulinoma, which
was not measured in situ owing to its unique location in the
cystic duct, mimicking a gallstone, and glucagonoma). The T/
B ratios in these two patients were exceptionally high: 910
(72 h after injection) and 1500 (48 h after injection).
Two patients (nos. 19 and 22) with negative scintigraphy
had negative probe findings (insulinoma and MEN I
proinsulinoma with microadenoma) (Table I).
In one patient with a gastric carcinoid (no. 18) studied
24 h after injection all probe measurements of macroscopic
tumours gave correct results for tumour locations in lymph
nodes and liver. The T/B ratios (71-210) were in the same
range as those seen in MC tumours.
One patient with a neuroendocrine carcinoma (no. 23) of
the uterine cervix had undergone a radical hysterectomy with
lymph node dissection. Based on scintigraphic uptakes in the
left renal parahilum and tail of the pancreas surgical
exploration was performed. In situ measurements of
macroscopic tumours gave incorrect results, maybe owing
to high background activity from the spleen and kidney. T/B
ratios were 8-130.
Discussion
Tumour localisation with octreotide scintigraphy and
intraoperative scintillation detection is dependent on the
presence of somatostatin receptors in the tumour tissue. In
the vast Rotterdam experience (Krenning et al., 1993) of
scintigraphy using "'In-labelled DTPA-D-Phe'-octreotide and
"23I-labelled Tyr3-octreotide 86% of patients with clinically
proven MC had otherwise diagnosed tumour sites visualised.
The corresponding figure for MTC patients was clearly lower,
65%. In a previous evaluation of the efficacy of scintigraphy
in MC patients we found a higher sensitivity than
conventional radiology (CT/US) and a high specificity
(Ahlman et al., 1994). In the present study T/B ratios varied
considerably between the different scintigraphy-positive
neuroendocrine tumour types; in MC tumours the ratio was
27-650, in a gastric carcinoid 71-210, in MTC 3-39 and in
EPT 910-1500. These high ratios would be expected to
facilitate detection of tumours with intraoperative scintilla-
tion detection in comparison with, for example, radio-
immunoguided surgery using radiolabelled monoclonal
antibodies (Curtet et al., 1990; Sardi et al., 1989). Earlier
limited studies on probe-guided surgery using radiolabelled
octreotide in patients with neuroendocrine tumours (Ahlman
et al., 1994; Schirmer et al., 1993; Waddington et al., 1994)
have been promising in individual patients. However, in this
study in situ measurements with the present detection system
(scintillation detector, ligand and isotope) gave lower ratios
than expected from the high T/B ratios and thus added
limited information to the preoperative scintigraphy and
macroscopic findings during surgery. Probe measurements
tend to underestimate the "'1In activity concentration of small
tumours. For comparative measurements ex vivo it is
therefore of importance to use samples of similar size. This
fact was strictly considered by both surgeons. During neck
dissections the probe was helpful in localising certain MTC
tumours, especially in the lateral part of the supraclavicular
triangle. One drawback was the relatively low signal from this
tumour type. Much higher signals were registered for two
MC patients who underwent neck exploration owing to
cervical metastases invading the vagal nerve. Probe measure-
a b
Localisation Type of Histopathological Rinsitu Rexvivo Ti/B
of tissue tissue tumour finding
Neck and Lymph node positive 1.3* 2.3* 31
mediastinum Lymph node positive 1.2* - 32
Lymph node positive 1.4* 4.0* 32
Lymph node negative 1.0 0.9 3.8
Fat negative 0.8 - 5.7
Figure 2 Intraoperative findings with scintillation detection and tissue to blood (Ti/B) ratios of "'1In activity in a patient with
recurrent lymph node metastases of medullary thyroid carcinoma. Preoperative (a) and postoperative scintigram (b) verifies the
complete excision ofscintigraphy-positive tumours in the neck and mediastinum. *Significantly higher count rates from tumour than
from adjacent normal tissue (P<0.05). R, right, L, left.["'in] DTPA-D-Phe'-octreotide in tumour detection
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ments in situ in abdominal surgery was less favourable as a
result of high background activity in parenchymatous organs.
The most reliable results were obtained for small bowel
tumours and mesenteric lymph nodes, which could be
mobilised away from possible background sources. In the
pelvic region discrimination seemed to be even better. One
exception is illustrated in Figure 1, where a parametrial cyst
gave a false-positive probe reading in spite of low Ti/B
values.
Of particular interest were the three MEN I patients, two
of whom had very high T/B ratios and correct intraoperative
measurements. The third patient had microadenomas and
negative intraoperative scintillation detection. Similarly,
microscopic tumour growth in lymph nodes (MC and
MTC) gave false-negative results. The ex vivo measure-
ments, with background "'1In activity eliminated, allowed
better discrimination between tumour-positive and tumour-
negative nodes in all three groups of patients. With further
development of the scintillation detector this technique may
be used as a rapid diagnostic complement to frozen tissue
biopsy.
Theoretically, probe-guided surgery would be most
beneficial in patients with recurrent MTC, when surgical
exploration is the only therapeutic option. In these patients
localisation of small metastases is technically demanding
(Tisell et al., 1986). In agreement with Krenning et al. (1993)
we found a distinct difference between MC and MTC
tumours regarding the sensitivity of scintigraphy. This was
also reflected by unreliable probe measurements and low T/B
ratios even in scintigraphy-positive MTC tumours. Our
preliminary studies have indicated that the discrepancy
between lymph node metastases of MC and MTC may be
in part due to a relatively lower tumour cell density in the
MTC patients, who had recurrent disease detected by
sensitive biochemical methods. Other factors may influence
the visualisation of somatostatin receptors and the sensitivity
of intraoperative scintillation detection: The expression of
different subtypes of receptors with varying binding affinity
for octreotide (Bruns et al., 1994) as well as varying receptor
densities (Reubi et al., 1991). The T/B ratios, R1nsi,u and
Rex vivo values found in this study were little influenced by the
time interval between injection of "'In-labelled DTPA-D-
Phe'-octreotide and surgery (24-168 h). This indicates a
similar decline in "'In activity of tumour and non-tumour
tissues, including blood, after the initial 24 h (Krenning et al.,
1992).
The total volume of the tumour is important for the
signal. This partly explains the marked difference in T/B
ratios between MC tumours and MTC. MTC patients,
undergoing neck re-exploration, often had lymph nodes
with microscopic tumour burden and consequently less total
"'In content than the large lymph node metastases of MC
tumours. In studies using radiolabelled monoclonal anti-
bodies on experimental tumours (Pedley et al., 1987; Williams
et al., 1988), a decreasing concentration has been shown with
increasing tumour size, but this has not been corroborated in
our studies on patients receiving "'In-labelled DTPA-D-Phe'-
octreotide (Forssell-Aronsson et al., 1995).
Considering the high T/B ratios for all tumours studied, in
comparison with the moderate ratios from the probe
measurements, future improvement of the technique must
be evaluated: (1) A different radionuclide emitting photons
with lower energy to reduce the contribution from adjacent
tissue, e.g. 1251 99Tc or '6tTb. (2) Modifications of the
scintillation detector, e.g. adjustable energy-window, adjus-
table collimator (for detection of tumours of various sizes),
peroperative statistical analysis of probe measurements and
angulated probe design (for work in restricted anatomical
spaces). The need for accurate localisation techniques of
small EPT and recurrent neck metastases of MTC should
encourage future research on intraoperative scintillation
detection using peptide receptors on tumour cells.
a b
Localisation of tissue Type of tissue Histopathological Rinsitu Rexvivo Ti/B
tumour finding
Pancreas Tumour Positive 4.9* 7.6* 910
Figure 3 Intraoperative findings with scintillation detection and tumour to blood (T/B) ratios of "'1In activity in a patient with
glucagonoma as part of the MEN I syndrome. Preoperative scintigraphy (a) shows high uptake of "'In-DTPA-D-Phel-octreotide in
the tail of the pancreas. No metastases are seen. Post-operative scintigraphy (right) shows normal background activity in liver,
kidneys and spleen. Significantly higher count rates from tumour than from adjacent normal tissue (P<0.05). R, right, L, left.["'in] DTPA-DrPhel-octi itwe our detectio
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